Secondary Renal Amyloidosis in Adult Onset Still's Disease: Case report and Review of the Literature

Young Bae Oh*, MD., Ph.D., Sang-Cheol Bae, MD., Ph.D., MPH.
Ja-Hun Jung, MD., Tae-Hwan Kim, MD., Ph.D., Jae-Bum Jun, MD., Ph.D.
Sung-Soo Jung, MD., Ph.D., In-Hong Lee, MD., Ph.D., Dae-Hyun Yoo, MD., Ph.D.
Moon Hyang Park**, MD., Ph.D. and Seong Yoon Kim, MD., Ph.D.

Department of Rheumatology *, Tong-Inchon Ghil Hospital,
Gachon Medical School, Inchon, 400-170, Korea
The Hospital for Rheumatic Diseases, Department of Internal Medicine, Department of Pathology ***, Hanyang University Medical Center, Seoul, 133-792, Korea

We report a 25-year-old Korean woman with Adult onset Still’s disease (AOSD) presented with renal amyloidosis, which had developed four years after disease onset. We successfully treated her with prednisolone, colchicine and cyclophosphamide. A review of the literature uncovered about 10 cases, most of which were treated by various regimens that resulted in poor outcomes. Renal amyloidosis should be suspected in patients with AOSD who have unexplained proteinuria. Although the mechanism of renal amyloid deposition is not well known, earlier histopathologic diagnosis and choice of regimen may affect prognosis.

Key Words: Adult onset Still’s disease; Amyloidosis

INTRODUCTION

Adult onset Still’s disease (AOSD) is a chronic systemic inflammatory disorder in which high spiking fever, typical skin rash, and polyarthritis occur. The main biological features are neutrophilic leukocytosis, hyperferritinemia, and negative rheumatoid factor (RF) or antinuclear antibodies (ANA). Others may include splenomegaly, pleuritis, pericarditis, and hepatic abnormalities1. Even though functional prognosis essentially depends on articular involvement, life-threatening prognosis depends on serious complications, such as hepatic failure, disseminated intravascular coagulopathy, hemophagocytosis, infections, amyloidosis, and cardiomyopathy2. In this article, we describe a patient with AOSD who had secondary renal amyloidosis. We suggest a successful combined therapy of prednisolone (PD), colchicine (COL), and cyclophosphamide (CTX) and review the literature.

CASE

A 25-year-old Korean woman was diagnosed with AOSD four years ago after experiencing a high spiking fever, maculopapular rash, and polyarthritis in her hands, elbows and knees. In laboratory findings, the leukocyte count was 19,900/μL, the serum ferritin level was 719.3 ng/mL (10-240), and RF and ANA were negative. During a follow-up, typical skin rash had disappeared after administration of PD, sulfasalazine or hydroxychloroquine and methotrexate (MTX), but either high fever or polyarthitis was wax and wane, and occasionally, intra-articular injections of corticosteroid were administered. In July 1998, she was admitted to our hospital because of slowly increasing proteinuria over a 7 month period without pitting edema or hypertension. She was single and had no family history of any rheumatic disease or drug history, such as gold or D-penicillamine.

The results of laboratory data showed that the white-cell count (WBC) was 12,800/μL, hemoglobin (Hb) was 10.6 g/dL, platelet was 610,000/μL, ESR was 61 mm/hr, and C-reactive protein (CRP) was 9.50 mg/dL (<0.8). The serum protein and albumin had decreased to 4.5 g/dL.
Serum ferritin was within the normal range. Serum autoantibodies and rheumatoid factor were persistently negative. There was no evidence of infection or malignancy. Several urine examinations showed proteinuria without any abnormality in urinary sediments. Twenty-four hour urine protein excretion was 6.9 g/day, and urine creatine clearance was 93.3 mL/min. In radiographic findings, chest PA was normal and bony erosions were detected in both wrist joints. In the sonography, the sizes of both kidneys were 11.5 cm on the right and 11 cm on the left side with increased renal parenchymal echogenicity.

Renal biopsy showed amorphous deposits in the mesangial areas, some glomerular capillary walls and in the vascular poles (Figure 1). The amyloid deposit stained with Congo red displayed apple-green birefringence under the polarizing light. Immunofluorescence study for IgG, IgM, IgA, C3, C1, C4, fibrinogen, albumin, and light chains showed segmental positive staining for IgM and C3 in the mesangium and trace (+) positive staining for light chain. Electron microscopic examination confirmed amyloid deposits in the mesangial areas, which were characterized by non-branching fibrils arranged in a random array (Figure 2A, 2B). Serum protein electrophoresis showed a decrease in both total protein and total albumin without a monoclonal spike. Urine protein electrophoresis showed an elevated total protein level and an elevated total albumin level. Therefore, the final diagnosis was made of secondary renal amyloidosis due to AOSD.

After one intravenous dosage of 500 mg methylprednisolone pulse therapy was administered. We maintained a high oral daily dose of PD (45 mg/day, 1 mg/kg), CTX (100 mg/day), and COL (1.2 mg/day). Two months later, the PD was tapered as proteinuria decreased. After a follow-up 15 months later, laboratory tests showed that the WBC was 6,000 /uL, Hb 13.2 g/dL, platelet 297,000 /L, ESR 11 mm/hr, CRP 0.11 mg/dL, and the serum protein and albumin had increased to 6.2 g/dL and 4.2 g/dL, respectively. The serum ferritin was 24.3 ng/mL. The urine protein clearance was decreased from 69 g/day to 92 mg/day. Currently, she is taking PD 7.5 mg, CTX 50 mg, and COL 12 mg orally.

DISCUSSION

AOSD is a disorder of unknown etiology and pathogenesis. The association of amyloid deposits and AOSD is rather unusual and should be considered a serious complication. The development of amyloidosis often
SECONDARY RENAL AMYLOIDOSIS IN ADULT ONSET STILL'S DISEASE: CASE REPORT AND REVIEW OF THE LITERATURE

occurs in patients with longstanding persistent inflammatory diseases. According to previous histopathologic reports on AOSD, complicated renal amyloidosis usually develops after 18 months to 30 years. The incidence of renal amyloidosis in AOSD reveals 4.7% to 14.3%.

We have experienced 45 patients with AOSD in our hospital and so far, found one case (2.2%) associated with renal amyloidosis, which had developed four years after the onset of AOSD.

When this complication occurs, amyloid material is preferentially deposited in the glomeruli, and proteinuria and nephrotic syndrome are the most common initial manifestations. There was no study regarding renal pathology in patients with AOSD. Helin et al. demonstrated in a retrospective study of nephropathy in rheumatoid arthritis (RA) that the most common histopathologic finding was mesangial glomerulonephritis (GN), followed by amyloidosis. Amyloidosis was the most common finding in nephrotic syndrome. In a patient with isolated proteinuria, amyloidosis, membranous GN, and mesangial GN were almost equally common. Membranous GN was closely related to gold or D-penicillamine therapies, whereas mesangial GN probably was related to RA itself. Biopsy is thus a valuable tool in differential diagnosis, assessment of prognosis, and decision-making with regard to treatment.

Although either NSAID or an oral steroid is usually effective in AOSD, some patients with complications of the renal amyloidosis may require sustained therapy with corticosteroid and a cytotoxic agent. The COL was also effective in a patient with severe ankylosing spondylitis and nephrotic syndrome due to amyloidosis. In review of 10 cases with AOSD complicated by renal amyloidosis, combined drug therapy with PD, COL, CTX, azathioprine, and MTX were used. In two of those cases, they were treated with steroids and dialysis due to renal failure. In our experience, it has persistently decreased proteinuria as well as recovered polyarthritis or fever, without any severe complications, during the combined therapy of PD, COL, and CTX (Table 1).

In conclusion, renal amyloidosis must be suspected in patients with AOSD who have unexplained proteinuria. Although the mechanism of renal amyloid deposition is unknown, early diagnosis and treatment with PD, COL, CTX may produce excellent results.

REFERENCES

1. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Murohima Y, Kashiwagi H, Kashiwazki S, Tanimoto K, Matsumoto Y, Ota T, Akizuki M. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19: 424-430, 1992

2. Pouchot J, Samplis JS, Beaudet F, Carette S, Decary F, Salussilsky-Stembach M, Hill RO, Gutkowski A, Harth M, Myhal D, Senechal JL, Yeadon C, Esdaile JM. Adult Still's disease: manifestation, disease course and outcome in 62 patients. Medicine 70:188-196, 1991

3. Fautrel B, Borget C, Rozenberg S, Meyer O, Loe XL, Masson C, Koeger AC, Kahn MF, Bougeois P. Corticosteroid sparing effect of lowdose methotrexate treatment in adult Still's disease. J Rheumatol 26: 373-378, 1999

Table 1. Comparison of renal amyloidosis diagnosed by renal biopsy in patients with adult onset Still's disease: published cases.

| Author (ref) | Age of disease onset, sex | Number of years before renal amyloidosis onset | Drug therapy for renal amyloidosis | Follow up duration after renal amyloidosis (months) | Outcome and complications |
|-------------|--------------------------|-----------------------------------------------|----------------------------------|-----------------------------------------------|--------------------------|
| Fautrel     | 32 M                     | ND                                            | PD, MTX                          | ND                                            | Death, Bone marrow aplasia |
| River       | 26 M                     | 16                                            | PD, AZA                          | ND                                            | Partial response          |
| Hashimoto   | 25 F                     | ND                                            | PD                               | 24                                            | ND                        |
| Ishii       | 32 M                     | 7                                             | PD, CTX                          | 16                                            | Death, Heart failure      |
| Bamberg     | 36 F                     | 8                                             | Steroid, dialysis                | ND                                            | Death, Renal failure      |
| Wendling    | 57 F                     | 4                                             | ND                               | 6                                             | Gastrointestinal amyloidosis |
| Vigneron    | 23 F                     | 1.5                                           | PD, hemodialysis                 | 6                                             | Death, Gastrointestinal amyloidosis & Renal failure |
| Harrington  | 26 F                     | 30                                            | PD, COL                          | 5                                             | Persistent proteinuria    |

Note: ND: non-described, PD: Prednisolone, MTX: methotrexate, AZA: Azathioprine, CTX: Cyclophosphamide, COL: colchicine.
4. Bambery P, Thomas RJ, Malhotra HS, Kaur U, Bhushan-math SR, Deodhar SD. Adult onset Still's disease: clinical experience with 18 patients over 15 years in northern India. Ann Rheum Dis 51:529-532, 1992
5. Gettz MA, Kyle RA. Amyloidosis: Prognosis and Treatment. Semin Arthritis Rheum 24:24-38, 1994
6. Helen HJ, Kospel MD, Mustonen JT, Pasternak AI. Renal biopsy findings and clinicopathologic correlations in Rheumatoid arthritis. Arthritis Rheum 38:242-247, 1995
7. Rivera F, Gil MC, Gil MT, Barke-Gualda E, Tiquerao M, Olivores J. Vascular renal AA amyloidosis in adult Still's disease. Nephrol Dial Transplant 2:174-178, 1997
8. Hashimoto M, Shingu M, Ezaki I, Yoshikawa Y, Nobunaga M. Clinical studies on 4 cases of adult-onset Still's disease. Nihon Rinsho Meneki Gakkai Kaishi 18:45-52, 1995
9. Ishii T, Sasaki T, Munoi T, Munai C, Hatakeyama A, Oosaki H, Yusa A, Kawanami T, Yoshinaga K. Systemic amyloidosis in a patient with adult onset Still's disease. Intern Med 32:50-52, 1993
10. Wendling D, Humbert PG, Bilkrey C, Fest T, Dupond JL. Adult onset Still’s disease and related renal amyloidosis. Ann Rheum Dis 50:257-259, 1991
11. Vigneron AM, Kaplan G, Labrousse C, Lenox-Robert C, Rene E, Kahn MF. Amyloidosis in adult Still’s disease. Apropos of 2 case. Ann Med Interne(Paris) 137:406-408, 1986
12. Harrington TM, Moran JJ, Davis Dc. Amyloidosis in adult onset Still's disease. J Rheumatol 8:833-836, 1981
13. Cho KS, Yoo DH, Yun HR, Lee MH, Lee JK, Shin SC, Chang DK, Yoo TS, Koh HK, Kim TH, Jun JB, Jung SS, Lee Il, Bae SC, Kim SY. Adult onset Still’s disease: Clinical features and prognostic factors in Korea. J Kor Rheum Ass 5:64-75, 1998
14. Escalante A, Ehrensmann GR, Quismorio FP. Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine. Arthritis Rheum 34:920-922, 1991